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Immune responses to exogenous antigens in infant experimental animals display various degrees of Th2
polarization. Preliminary evidence from small human studies suggest a similar age-dependent response
pattern to vaccines, but detailed investigations on vaccine immunity during infancy have not yet been under-
taken. We report below the results of a comprehensive prospective study on responses to the tetanus component
of the diphtheria, tetanus, acellular pertussis (DTaP) vaccine in a cohort of 55 healthy children, employing
peripheral blood mononuclear cells (PBMC) collected at the 2-, 4-, and 6-month vaccinations and at 12 months.
Antigen-specific production of interleukin-4 (IL-4), IL-5, IL-6, IL-9, IL-10, IL-13, and gamma interferon
(IFN-g) was determined at each sample point, in parallel with polyclonal (phytohemagglutinin PHA-induced)
cytokine responses. Our results indicate early and persistent Th2 responses to the vaccine, in contrast to a
more delayed and transient pattern of IFN-g production. This initial disparity between the Th1 and Th2
components of the vaccine response was mirrored by patterns of polyclonally induced cytokine production,
suggesting that the delayed maturation of the Th1 component of the vaccine response during infancy is
secondary to developmental processes occurring within the overall Th cell system.
The current schedule for vaccination of infants with the
diphtheria, tetanus, acellular pertussis (DTaP) vaccine is the
subject of increasing debate, in particular the relationship be-
tween the timing and frequency of dosing and the subsequent
generation of immunological memory. The nature of the re-
sponse to the initial cycle of three primary vaccinations given
during infancy represents the least understood aspect of this
question. Although systematic kinetic studies have been con-
ducted on antibody responses, studies of cellular responses in
large samples of subjects over this age range have not yet been
performed.
Of particular interest in this context are vaccine antigen-
specific T-helper (Th)-cell cytokine responses during early in-
fancy. It is evident from a number of clinical efficacy trials
focusing on the pertussis component of the vaccine that pro-
tection against infection does not correlate consistently with
specific serum antibody titer (1, 8, 11, 12, 22, 24). This argues
that other aspects of the host response (notably cellular im-
munity) may also be important in the defense against infection,
and this conclusion is reinforced by results from animal model
systems which demonstrate a key role for cytokine-secreting
CD41 T cells, in particular T cells secreting Th1 cytokines, in
protection against respiratory tract challenge with pertussis
(15, 17). Similarly, in terms of adult responses to tetanus toxoid
(TT), both Th1 and Th2 cytokines have been implicated in
vaccine-induced protection (9, 10).
However, recent studies in mice (6, 20, 23), and also in
humans (reviewed in reference 13) suggest that the capacity to
generate both acute and persistent Th1 responses to antigen
challenge during the early postnatal period is normally com-
promised, unless selective Th1 stimulants are coadministered
with the antigen. In relation to the development of cellular
immunity during the early phase of DTaP vaccination in hu-
mans, detailed information on the kinetics, range, and magni-
tude of responses during infancy is lacking, since the only
available information is limited to two small studies focusing
on pertussis-specific production of a limited range of cytokines
4 weeks after completion of the initial course of three primary
vaccinations (3, 28).
The present study focuses on tetanus-specific responses in a
cohort of children; it uses blood samples collected at the time
of the 2-, 4-, and 6-month primary vaccinations and contrasts
these with a further sample collected at 12 months. Specific
responses were measured by determining the production of a
comprehensive range of cytokines at the protein (interleukin-5
[IL-5], IL-6, IL-10, IL-13, and gamma interferon [IFN-g]) and
mRNA (IL-4 and IL-9) levels. Postnatal maturation of overall
Th1 and Th2 functions was monitored in parallel cultures by
measurement of cytokine production triggered by the poly-
clonal stimulant phytohemagglutinin (PHA).
Our results indicate divergent patterns of vaccine antigen-
specific Th1 and Th2 cytokine production in human infants
which are broadly consistent with recent studies in infant mice
(5), i.e., initial polarization towards the Th2 cytokine pheno-
type and relatively poor persistence of the Th1 component of
the response. Moreover, the relative Th2 bias of these early
antigen-specific responses is mirrored by cytokine patterns ob-
tained with the polyclonal stimulant PHA, suggesting that the
principal rate-limiting determinants of the host response to the
vaccine during infancy are factors intrinsic to the postnatal
development of the Th cell system.
MATERIALS AND METHODS
DTaP vaccine. DTaP vaccine (Infanrix; SmithKline Beecham, Rixensart, Bel-
gium) contained 25 Lf of diphtheria toxoid, 10 Lf of TT, 25 mg of pertussis
toxoid, 25 mg of filamentous hemagglutinin and 8 mg of pertactin adsorbed onto
0.5 mg of aluminum (aluminum hydroxide).
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Subjects. Fifty-five healthy subjects were recruited into this study at 2 months
of age. The infants received DTaP at 2, 4, and 6 months of age, in addition to the
oral polio (SmithKline Beecham) and HibTitre (Lederle) vaccines. Prior to
immunization, peripheral blood was obtained at these time points, as well as at
12 months; samples were obtained from $78% of the group on each occasion.
Blood was collected into an equal volume of RPMI 1640 (Cytosystems, Castle
Hill, Australia) containing preservative-free heparin. Peripheral blood mononu-
clear cells (PBMC) were isolated and cryopreserved at collection as previously
described (25). This study was carried out with the approval of the Princess
Margaret Hospital Ethics Committee (Perth, Australia), and written informed
consent was provided by the parents or guardians of all the children.
Cell preparation and culture. The studies were performed with PBMC which
had been cryopreserved at collection; previous studies from our laboratory (14,
25) and elsewhere (2) have demonstrated that this procedure does not distort
PBMC cellular immune responses.
PBMC which had been cryopreserved were thawed and resuspended at 106
viable cells/ml in either RPMI 1640 supplemented with 5% pooled human AB
serum (for cultures with TT) or AIM-V serum-free medium (Gibco Life Tech-
nologies, Waverley, Australia) supplemented with 2-mercaptoethanol (4 3 1025
M final concentration [Sigma, Castle Hill, Australia]) (for cultures with PHA).
Aliquots of 0.5 to 1.0 ml from each individual were cultured at 37°C under 5%
CO2 for 48 h as follows: medium alone or medium containing TT (0.5 Lf/ml
[CSL, Parkville, Australia]) or PHA (HA16; 1 mg/ml [Murex, Northmead, Aus-
tralia]). After culture, the cells were collected by centrifugation and used imme-
diately for RNA extraction while the supernatants were stored at 220°C for
enzyme-linked immunosorbent assays ELISA.
Semiquantitative reverse transcription-PCR detection of cytokine-specific
mRNA. Total RNA from the cell pellets was obtained using RNAzol B extracting
solution as previously described (27). cDNA was transcribed in a total volume of
25 ml at 42°C using oligo (dT)15 (250 ng [Biotech International, Bentley, Aus-
tralia]) and avian myeloblastosis virus (AMV) reverse transcriptase (4.5 U [Pro-
mega, Madison, Wis.]) in the presence of RNase inhibitor (10 U [RNaseOUT;
Biotech]). cDNA was amplified for b-actin, IL-4, and IL-9. The PCR mixture
contained 1 ml of cDNA, 50 ng of the specific primers (Gibco), 13 PCR buffer
(Gibco), 0.2 mM each deoxynucleoside triphosphate (Biotech), 1.5 mM MgCl2
(Gibco), and 0.5 U of Platinum Taq DNA polymerase (Gibco) in a total volume
of 12.5 ml overlaid with mineral oil. The PCR was run as follows: an initial
denaturation step of 94°C for 3 min, denaturation at 94°C for 1 min, annealing
at respective temperatures for 1 min, and extension at 72°C for 1 min. All
reactions were performed in a programmable thermocycler (Perkin-Elmer, Mel-
bourne, Australia). A positive cDNA control was always amplified in parallel in
all PCRs performed.
Primers. As described previously (27), the sequences for the primers were as
shown in Table 1. Rigorous cycle analyses were performed with each primer set
to ensure that we had reached detection levels and that the reaction remained in
the linear phase (30 cycles for b-actin, 43 cycles for IL-4, and 40 cycles for IL-9).
In each case, PCR products of the expected size were obtained, as verified by
analysis in a 1.5% agarose gel and staining with ethidium bromide of a subset of
samples and a positive control.
Slot-blot analysis, hybridization, and detection. The PCR products were an-
alyzed by slot-blot analysis (Hoefer Scientific Instruments, San Francisco, Calif.),
a modification of previously described methods (27). Briefly, double-stranded
probes were produced by PCRs using biotin-16-dUTP (Boehringer Mannheim,
Perth, Australia) at a ratio of 5:1. The template for probe synthesis was cDNA
obtained from adult PBMC stimulated with PHA (1 mg/ml) for 24 h at 37°C.
Following overnight hybridization with biotinylated probes, the binding was
visualized by chemiluminescence using a commercial kit (ECL; Amersham, Little
Chalfont, United Kingdom) as specified by the manufacturer. The membranes
were exposed to hyperfilm (Amersham), and the intensity of each dot was
determined using a densitometer (Scan Analysis 2.02; Biosoft, Cambridge,
United Kingdom). The results were then expressed as a ratio of cytokine to
b-actin density.
ELISAs for detection of cytokine protein. The level of IL-6, IL-13, and IFN-g
in the supernatants were determined by using commercially available ELISA kits
(PeliKine CompactTM CLB, Amsterdam, The Netherlands). The sensitivity of
the assay was 5 pg/ml for IL-6, 3 pg/ml for IL-13, and 4 pg/ml for IFN-g. IL-5
protein was measured by an in-house ELISA, using rat immunoglobulin G1
(IgG1) anti-human IL-5 monoclonal antibody (clone TRFK5; Pharmingen, San
Diego, Calif.) for capture and biotinylated rat IgG2a anti-IL-5 monoclonal an-
tibody (clone JES1-5 A10; Pharmingen) for detection. The standard curve was
generated using serial dilutions of recombinant human IL-5 (Pharmingen); the
limit of detection was 6 pg/ml. IL-10 protein was also measured by an in-house
ELISA, using rat IgG1 anti-human IL-10 monoclonal antibody (clone JES3-9D7;
Pharmingen) for capture and biotinylated rat IgG2a anti-human IL-10 mono-
clonal antibody (clone JES3-12G8; Pharmingen) for detection. For the standard
curve, we used recombinant human IL-10 (Pharmingen); the limit of detection
was 4 pg/ml.
Statistical analysis. Cytokine responses induced by TT and PHA were ana-
lyzed by the Wilcoxon matched-pairs signed rank test for paired responses. The
statistical package StatView 5.0.1 was used.
RESULTS
Vaccine antigen-specific cytokine responses. The vaccine an-
tigen-specific cytokine responses are illustrated in Fig. 1. At the
2-month bleed, prior to vaccination, TT antigen-induced IL-5,
IL-13, IFN-g, IL-4, and IL-9 responses were infrequent and
extremely low. Cytokine protein responses remained low at the
4-month bleed, but IL-4 and IL-9 were detectable at the
mRNA level. At 6 and 12 months, the Th2 cytokine responses
were increased (IL-5 and IL-13 protein) or sustained (IL-4 and
IL-9 mRNA) compared to the responses seen at 4 months. In
contrast, IFN-g responses peaked in frequency (45%) and in-
tensity at 6 months but waned significantly by 12 months. At
the population level, antigen-induced IL-6 and IL-10 produc-
tion was not significant but low-level responses were observed
in approximately 15% of children for IL-6, including at the
prevaccination bleed (data not shown); indirect evidence from
other studies (18) suggests that the principal source of IL-6
here consists of monocytes armed with transplacentally trans-
ferred maternal antibody.
Age-related changes in cytokine production capacity. The
experiments in Fig. 2 sought to document developmental
changes in cytokine production capacity over the first 12
months of life, employing polyclonal PHA stimulation.
As an example of the Th2 cytokine compartment, produc-
tion of IL-5 and IL-13 was compared at the four time points
shown. IL-5 production capacity began to rise after 4 months,
and production levels of both IL-5 and IL-13 at 12 months
were significantly elevated over those observed at earlier sam-
pling points. In contrast, IFN-g production levels did not rise
over the same period; IFN-g responses in PBMC from age 12
months were approximately sixfold lower than those observed
in 6-year-old children stimulated under identical conditions
(data not shown).
DISCUSSION
The range of vaccines used in pediatric practice is increasing,
and further increases can be expected in the medium-term
future. However, our level of understanding of the nature of
vaccine-induced immune responses in human infants has re-
mained relatively static. The present study addresses this im-
portant issue at a very basic level, by assessment of time-
dependent changes in Th-cell responses to TT antigen in a
cohort of 55 infants undergoing DTaP vaccination.
The relevant information already available in the literature
relating to infants is restricted to two recent reports on a
limited range of specific cytokine responses to pertussis anti-
gens, studied at 1 month after completion of the three-step
“primary vaccination” schedule (3, 28), at which time the re-
sponses may be expected to approximate peak levels. In con-
trast, the present study examined the production of seven cy-
tokines in response to TT at four time points up to age 12
TABLE 1. Primers used in this study
Primer Sequence (59339) Annealingtemp (°C)
Product
size (bp)
b-actin F CGT GAC ATT AAG GAG AAG CTG TGC 58 375
b-actin R CCT AGG AGG AGC AAT GAT CTT GAT
IL-4 F CAA GTG CGA TAT CAC CTT ACA GG 58 306
IL-4 R CCT TCA CAG GAC AGG AAT TCA AGC
IL-9 F GGG ATC CTG GAC ATC AAC TT 56 307
IL-9 R CAG AAG ACT CTT CAG AAA TG
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months, an age midway between the final “primary” dose at 6
months and the first booster (due at age 18 months).
The salient findings from these studies are as follows. First,
as reported previously (3, 28), levels of cytokine production
exhibit large variations between individual infants. However,
clear statistically significant population responses were ob-
served in this cohort, especially after the two initial vaccine
doses, by which time approximately half of the group exhibited
positive IL-4, IL-9, IL-13, and IFN-g responses and around
one-third were positive for IL-5. The detection of IL-9 and
IL-4 mRNA in the early phase of these responses is interesting,
since, together with the parallel findings on the presence of
IL-5 and IL-13 protein, this emphasizes the strong contribution
of the Th2 cytokine compartment to these early vaccine re-
sponses. We have reported similar findings recently with re-
spect to responses in infants to nonvaccine antigens from the
FIG. 1. TT-specific cytokine production by PBMC. The data shown illustrate TT-specific cytokine responses in infants undergoing DTaP vaccination, as detailed
in Materials and Methods. The results are presented as box plots. The limits of the boxes represent the 25th and 75th percentiles of the results. The enclosed line
represents the median (50th percentile), and the bars represent the 10th and 90th percentiles. (A) The cytokine protein content of culture supernatants was assayed
by ELISA and expressed as picograms per milliliter. (B) Cytokine-specific mRNA was determined by semiquantitative reverse transcription-PCR and is presented as
a ratio relative to b-actin. The data are expressed as delta values (treatment minus control) from those positively responding to TT (a twofold increase above control
production was defined as a positive cytokine response; percentages are shown in parentheses). The significance of differences between test and control cultures within
the overall study population, and between the various sampling points, was determined using the Wilcoxon matched-pairs signed rank test for paired responses (p, P ,
0.05; pp, P , 0.01; ppp, P , 0.0001).
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normal environment, which are encountered at mucosal sur-
faces (13, 19, 27).
These early responses to the TT component of the DTaP
vaccine are not restricted exclusively to Th2 cytokines, since
significant production of IFN-g was noted at the 6-month time
point in response to TT. The presence of this mixed response
is consistent with an earlier report (10) on a small number of
adults boosted with TT.
The key difference between the Th1 and Th2 arms of these
responses is not evident until the 12-month bleed. As noted in
Fig. 1, unlike the Th2 cytokine responses, which are relatively
stable between 6 and 12 months, the IFN-g component signif-
icantly declines during this period, suggesting that Th memory
development in the Th1 compartment is poor at this age.
These findings are consistent with recent findings with infant
mice, which are capable of initiating significant primary Th1
and Th2 responses but in which the subsequent Th memory
generation is largely restricted to the Th2 component (4, 5, 7,
23).
The overall Th2 polarity of immune responses during in-
fancy reflects the situation in the fetal compartment, in which
Th1 responses are actively suppressed via a variety of control
mechanisms in order to protect the placenta against the toxic
effects of IFN-g (26). It is clear, however, that this Th1 defi-
ciency is not absolute, since our current findings and those
from earlier studies on infant responses to the DTP vaccine
(21) demonstrate moderate IFN-g production in a proportion
of subjects; additionally, strong Th1 responses can be readily
stimulated in early infancy with more powerful stimulants such
as BCG (16), as has been observed in mice (4). However, this
is equally clearly not the case with less potent antigens, which
lack intrinsic Th1-stimulatory properties such as environmen-
tal allergens (13, 19, 27), and the relatively low capacity to
express Th1 immunity during infancy has been suggested to be
an important factor in the development of Th1- versus Th2-
biased immunity to these agents during early life (13).
Figure 1 suggests that this general paradigm may also be
applicable to DTaP vaccine-specific immune responses during
infancy. It can be seen that after an initial lag during the
immediate postnatal period, the capacity of PBMC from in-
fants in this cohort to produce the archetypal Th2 cytokines
IL-5 and IL-13 following polyclonal stimulation increases
markedly (Fig. 2). This increase broadly parallels the age-
related contribution of these two cytokines to the respective
TT-specific responses. In contrast, IFN-g responses to TT were
transient and usually waned between the last inoculation at 6
months and the final PBMC collection at 12 months. The
failure of this component of the response to persist after pri-
mary vaccination is paralleled by the apparent failure of overall
IFN-g production capacity to expand beyond the initial neo-
natal range (Fig. 2).
These results suggest that during the period between pri-
mary vaccination and boosting (due at 18 months), the level of
DTaP vaccine-specific cell-mediated immunity may be rela-
tively low. If recent suggestions that protective immunity
against agents covered by the DTP vaccine relies in part upon
a cellular (Th1) response component (21) prove to be correct,
it may be hypothesized that the phase between primary vacci-
nation and first boost represents a potential “window of in-
creased risk” for infection, due to failure of maturation of the
Th1 component of the vaccine-driven response. Further re-
search is required to clarify this important issue. It is also
possible that aspects of the initial cytokine responses to the
vaccine may to some degree be predictive of quantitative
and/or qualitative aspects of ensuing memory, and this possi-
bility will also be examined in longer-term follow-up studies.
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